Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

HQL

HOLD

Abrdn Life Sciences Investors · Financial Services · United States · $585M · Avg Vol: $3M/d

46
StockRank
Get insider-trade alerts
Q
33
V
48
M
58
P/E (TTM)
2.9x
ROE
41.4%
D/E
0.0x
Dividend %
10.0%

COMPANY DESCRIPTION

abrdn Life Sciences Investors is a closed-end fund that invests in public and private companies within the life sciences industry, including biotechnology, pharmaceuticals, and medical devices. The fund's competitive advantage lies in its ability to invest a portion of its assets in venture-stage, privately held companies, offering retail investors rare access to early-stage healthcare innovations. It is managed by abrdn's specialized healthcare team, targeting long-term capital appreciation through a diversified portfolio of cutting-edge science companies.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGRTTM
Revenue-103.3M23.5M86.7M86.4M91.6%
EPS2.66-4.260.793.042.791.2%6.64
Shares25.7M26.8M28.1M29.6M+15.3%
Debt
Equity397.9M401.9M459.7M513.7M8.9%
Op CF31.7M39.8M
Inv CF
Fin CF-31.6M
Loading 1Y...
PRICE (1Y)+6.3%
17.9618.6819.3920.1120.83Jun 18Jul 13Jul 31
SMA 50SMA 200
Close
$19.10
RSI (14)
35.3
52W High
$21.32
From 52W High
0.9%

SCORE BREAKDOWN

Quality
33
ROIC (ROA)
-0.6%*9.5
ROE
41.4%97.0
GP/Assets
0.2%3.4
Op. Margin
-516.5%1.2
FCF/Assets
-0.8%16.2
Piotroski
212.8
Int. Cover
N/A
D/E Ratio
0.00x94.8
Current Ratio
1.61x51.1
Value
48
P/E (TTM)
2.9x98.4
EV/EBITDA
N/A
P/FCF
N/A
P/B
1.0x56.3
P/S
0.3
Div Yield
10.0%89.9
Momentum
58
52W High %
90%43.0
RS 6M
11%79.3
SMA 50/200
1.12x78.9
EPS Rev 4W
N/A
EPS Rev 12W
N/A
EPS Improve
N/A
Q Growth
N/A

FUNDAMENTALS

Market Cap
$585M
P/E (Forward)
Gross Margin
100.0%

SECTOR PEERS

Closest peers in Financial Services, ranked by industry match, size, and score similarity. Cross-listings of HQL are excluded.

TickerCompanyMkt CapStockRankSignal
HQLAbrdn Life Sciences Investors(you)$585M46HOLD
VGMInvesco Trust for Investment Grade Municipals$549M48HOLD
VCVInvesco California Value Municipal Income Trust$515M47HOLD
DSUBlackRock Debt Strategies Fund, Inc.$591M50HOLD
PMLPIMCO Municipal Income Fund II$485M47HOLD
RABrookfield Real Assets Income Fund Inc.$703M47HOLD
RMTRoyce Micro-Cap Trust, Inc.$736M46HOLD
MUABlackRock MuniAssets Fund, Inc.$527M44HOLD
GUTThe Gabelli Utility Trust$576M41HOLD
PFLTPennantPark Floating Rate Capital Ltd.$681M48HOLD

Peer medians: ROE 9.6% · P/E 13.5x · Gross margin 100.0%

Abrdn Life Sciences Investors (HQL): Stock Score Summary

Abrdn Life Sciences Investors (HQL) has a MoatMap StockRank of 46/100 based on Quality (33/100), Value (48/100), and Momentum (58/100) factor scores. The current signal is HOLD.

abrdn Life Sciences Investors is a closed-end fund that invests in public and private companies within the life sciences industry, including biotechnology, pharmaceuticals, and medical devices. The fund's competitive advantage lies in its ability to invest a portion of its assets in venture-stage, privately held companies, offering retail investors rare access to early-stage healthcare innovations. It is managed by abrdn's specialized healthcare team, targeting long-term capital appreciation through a diversified portfolio of cutting-edge science companies.

Key Financial Metrics

Price$19.10
Market Cap$585M
P/E (TTM)2.90
Price/Book1.04
Return on Equity41.4%
Debt/Equity0.00x
Gross Margin100.0%
Operating Margin-516.5%
Revenue Growth-60.8%
Dividend Yield10.0%
Free Cash Flow$-4M

Abrdn Life Sciences Investors operates in the Asset Management industry, part of the Financial Services sector (United States).

Frequently Asked Questions

What is Abrdn Life Sciences Investors’s (HQL) StockRank?
MoatMap’s StockRank for Abrdn Life Sciences Investors (HQL) is 46/100, with a Hold signal. It is a composite of Quality (33), Value (48), and Momentum (58) factor ranks across MoatMap’s 20,000+ stock universe.
Does Abrdn Life Sciences Investors have an economic moat?
Abrdn Life Sciences Investors (HQL) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Abrdn Life Sciences Investors a buy, hold, or sell?
MoatMap’s current signal for Abrdn Life Sciences Investors (HQL) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Abrdn Life Sciences Investors in?
Abrdn Life Sciences Investors (HQL) operates in the Financial Services sector, specifically the Asset Management industry (United States).